Register of the intention to issue the temporary Schedule I status; the temporary status will become official 30 days after the publication of the notice in the Federal Register . The temporary status is in effect for 2 years, with a potential extension of 1 additional year. Human clinical trials may determine whether the substance produces adverse effects sufficient to provide an imminent hazard to public safety. Once the DEA receives scientific and medical evaluation from the secretary of the HHS, an interim final rule is issued, which becomes effective immediately (DEA, 2018c). Recently, the DEA has invoked the right to assign a substance Schedule I status based on an imminent hazard to public safety for substances identified as controlled substance analogs. A controlled substance analog intended for human consumption is structurally or pharmacologically substantially similar to a Schedule I or Schedule II substance. It is not an FDA-approved medication in the United States (DEA, 2018b). Under federal law, any controlled substance analog is considered a Schedule Schedules of controlled substances A complete list of the scheduled controlled substances is published annually in the DEA regulations (Title 21 of the Code of Federal Regulations (CFR) , Sections 1308.11 through 1308.15). These lists describe the primary or parent compound and do not include the salts, esters, or salts of isomers that may be controlled substances. Therefore, a substance may be regulated as a controlled substance analog even though it is not included on these lists. Final rules are found in the Federal Register before the publication of the next CFR (DEA, 2018c). Schedule I Controlled Substances Substances in this class have no accepted medical use within the United States, lack appropriate safety levels under medical supervision, and have a high level of abuse (DEA, 2018b). Examples include: ● Heroin. ● Marijuana (cannabis). ● Peyotes. ● Methylene-dimethoxy-methamphetamine (MDMA [ecstasy]). Lysergic acid diethylamide (LSD). The CSA allows medical research on Schedule I substances if the researcher is certified by the FDA and the research protocol is approved. Researchers who meet these criteria must obtain separate registration from the DEA to conduct research with Schedule I substances (DEA, 2020b). Such research is essential to determine if a given substance offers any medical benefit and to identify other safety factors, such as drug interactions and possible adverse effects. Schedule II/IIN Controlled Substances Substances in this class have a high potential for abuse that may lead to severe psychological or physical dependence, and they also have accepted medical use (DEA, 2018b). Examples of Schedule II narcotics: ● Codeine. ● Hydrocodone (Vicodin, Zohydro ER). ● Hydromorphone (Dilaudid).
I controlled substance (DEA, 2022a). Commonly controlled substance analogs include synthetic cannabinoids and synthetic opioids, particularly fentanyl. In addition, substances found in illicit substances of abuse, such as K2 or “spice” (i.e., synthetic cannabinoids), heroin (i.e., synthetic fentanyl compounds), “bath salts,” or other new psychoactive substances (e.g., synthetic cathinones). Abuse of these synthetic compounds has increased significantly, leading to clinical management challenges for first responders and emergency medicine clinicians. Healthcare Consideration: Prescribers must be able to differentiate between the various controlled substance schedules and know the types of drugs in each schedule on a federal and state level. This allows nurse practitioners to adhere to legal mandates and appropriately control and monitor the distribution of such drugs and their effects on patients. Schedule III/IIIN Controlled Substances Substances in this schedule have less of a potential for abuse than substances in Schedules I and II, and abuse may lead to low to moderate physical dependence and high psychological dependence (DEA, 2018b). Examples of Schedule III narcotics: ● Products containing no more than 90 mg of codeine (Tylenol with Codeine). ● Buprenorphine (Suboxone). Examples of Schedule IIIN non-narcotics: ● Benzphetamine (Didrex). ● Butalbital (Fiorinal). ● Dronabinol (Marinol). ● Ketamine. ● Anabolic steroids. ● Testosterone (Androderm). Schedule IV Controlled Substances Substances in this schedule have a low potential for abuse
relative to substances in Schedule III (DEA, 2018b). Examples of Schedule IV controlled substances:
● Alprazolam (Xanax). ● Carisoprodol (Soma). ● Clonazepam (Klonopin). ● Clorazepate (Tranxene). ● Diazepam (Valium). ● Eszopiclone (Lunesta). ● Lorazepam (Ativan). ● Midazolam (Versed). ● Modafinil (Provigil). ● Phenteramine (Adipex-P). ● Temazepam (Restoril).
● Triazolam (Halcion). ● Zaleplon (Sonata). ● Zolpidem (Ambien). Schedule V Controlled Substances
● Methadone (Dolophine). ● Meperidine (Demerol). ● Morphine (MSContin, Roxanol). ● Opium. ● Oxycodone (Roxicodone, OxyContin, Percocet). ● Fentanyl (Sublimaze, Duragesic). Examples of Schedule IIN non-narcotics: ● Amobarbital. ● Amphetamine (Dexedrine, Adderall). ● Nabilone (Cesamet). ● Methamphetamine (Desoxyn). ● Methylphenidate (Ritalin). ● Pentobarbital.
Substances in this schedule have a low potential for abuse relative to substances in Schedule IV and primarily include preparations containing limited quantities of certain narcotics (DEA, 2018b). Examples of Schedule V controlled substances: ● Cough preparations containing not more than codeine 200 mg/100 mL or codeine 200 mg/100 mg (Robitussin AC, Phenergan with Codeine). ● Diphenoxylate (Lomotil).
● Lacosamide (Vimpat). ● Opium preparations. ● Pregabalin (Lyrica).
EliteLearning.com/ Dental
Book Code: DFL3024
Page 13
Powered by FlippingBook